,text,position,name,last,events,dateString,collapsed,checked
0,"<p>New funding applications are referred to one of Pharmac's Funding Application Advisors (FAAs), who'll review the application to ensure they have the relevant information to undertake a preliminary analysis.&nbsp; They may seek more information if required.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/</a></p>",0,Application Received,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'May 2020', 'fs': 'May 2020', 'change': None}, 'Event_Description': {'s': 'Application received', 'fs': 'Application received', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000EZ28g2AD'}, 'Id': 'a0POZ00000EZ28g2AD', 'Event_Date__c': '2020-05-25', 'Event_Description__c': 'Application received', 'Stage__c': 'Application Received', 'Formatted_Date__c': 'May 2020', 'Status_History__c': 'a132P000000BwUtQAK'}, 'change': None}]",May 2020,False,True
1,"<p>Pharmac is identifying and gathering information required to get clinical advice.  The <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/"" rel=""nofollow"">Pharmacology and Therapeutics Advisory Committee (PTAC)</a>  meets quarterly. There are also around 20 expert <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/"" rel=""nofollow"">Specialist Advisory Committees (SACs)</a>, previously expert Subcommittees, which provide clinical evaluations in specialist areas. Specialist Advisory Committees meet as required to discuss issues referred to them by PTAC or Pharmac.</p>
<p style=""height: 20px"">&nbsp;</p>
<p>In November 2021, we introduced separate terms of reference for the SACs to make clear that these committees have different, but complementary, roles, expertise and perspectives to PTAC.</p>
<p style=""height: 15px"">&nbsp;</p>
<p>PTAC and SACs may make recommendations to Pharmac that differ from each other when looking at the same evidence. Pharmac considers the recommendations provided by all our clinical advisory committees when assessing applications.</p>
<p style=""height: 20px"">&nbsp;</p>
<p><a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/ptac-terms-of-reference-july-2021/"" rel=""nofollow"">PTAC</a>  and <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/specialist-advisory-committee-terms-of-reference//"" rel=""nofollow"">Specialist Advisory Committees</a> records of the meeting will be published on this website in accordance with the Terms of Reference.</p>",1,Seeking Clinical Advice,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jul 2020', 'fs': 'Jul 2020', 'change': None}, 'Event_Description': {'s': 'Clinical advice required', 'fs': 'Clinical advice required', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000EZ28h2AD'}, 'Id': 'a0POZ00000EZ28h2AD', 'Event_Date__c': '2020-07-10', 'Event_Description__c': 'Clinical advice required', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Jul 2020', 'Status_History__c': 'a132P000000BwUyQAK'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Sep 2020', 'fs': 'Sep 2020', 'change': None}, 'Event_Description': {'s': 'Assigned to Cancer Treatments Subcommittee (CaTSoP) meeting to provide advice on Friday 16 October 2020', 'fs': 'Assigned to Cancer Treatments Subcommittee (CaTSoP) meeting to provide advice on Friday 16 October 2020', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000EZ28i2AD'}, 'Id': 'a0POZ00000EZ28i2AD', 'Event_Date__c': '2020-09-21', 'Event_Description__c': 'Assigned to Cancer Treatments Subcommittee (CaTSoP) meeting to provide advice on Friday 16 October 2020', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Sep 2020', 'Status_History__c': 'a132P000000CBZTQA4'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Sep 2020', 'fs': 'Sep 2020', 'change': None}, 'Event_Description': {'s': 'Assigned to Cancer Treatments Subcommittee (CaTSoP) meeting to provide advice on Friday 16 October 2020', 'fs': 'Assigned to Cancer Treatments Subcommittee (CaTSoP) meeting to provide advice on Friday 16 October 2020', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000EZ28j2AD'}, 'Id': 'a0POZ00000EZ28j2AD', 'Event_Date__c': '2020-09-22', 'Event_Description__c': 'Assigned to Cancer Treatments Subcommittee (CaTSoP) meeting to provide advice on Friday 16 October 2020', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Sep 2020', 'Status_History__c': 'a132P000000CBnCQAW'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee <b>recommended</b> that lenvatinib in combination with everolimus be funded for patients with advanced renal cell carcinoma who have progressed after one prior targeted therapy for the second-line treatment of patients with metastatic renal cell carcinoma with a <b>medium priority</b>, within the context of treatment of malignancy, subject to the following Special Authority criteria:\xa0\xa0</p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">LENVATINIB</span></p><p style=""text-align: justify;""><b style=""font-size: 9pt;"">Initial application</b><span style=""font-size: 9pt;""> from a relevant specialist or any other medical practitioner on the recommendation of a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria:</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">All of the following:</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">1 The patient has metastatic clear cell renal cell carcinoma; and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">2 The patient has received one prior line of targeted treatment; and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">3 The patient has good performance status (WHO/ECOG grade 0-1); and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">4 Lenvatinib with be prescribed in combination with everolimus </span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">\xa0</span></p><p style=""text-align: justify;""><b style=""font-size: 9pt;"">Renewal –</b><span style=""font-size: 9pt;""> (renal cell carcinoma) only from a relevant oncologist or gastroenterologist or hepatologist. Approvals valid for 3 months for applications meeting the following criteria:</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">All of the following:</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">1 No evidence of disease progression; and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">2 The treatment remains appropriate and the patient is benefitting from treatment</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">\xa0</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">Notes: Lenvatinib with everolimus treatment should be stopped if disease progresses.</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">\xa0</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">\xa0</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">EVEROLIMUS</span></p><p style=""text-align: justify;""><b style=""font-size: 9pt;"">Initial application</b><span style=""font-size: 9pt;""> — (RCC in combination with lenvatinib) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria:</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">1 The patient has histologically verified metastatic clear cell renal cell carcinoma; and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">2 The patient has received one prior line of targeted treatment; and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">3 Must be used in combination with lenvatinib </span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">\xa0</span></p><p style=""text-align: justify;""><b style=""font-size: 9pt;"">Renewal –</b><span style=""font-size: 9pt;""> (RCC in combination with lenvatinib) only from a relevant oncologist or gastroenterologist or hepatologist. Approvals valid for 3 months for applications meeting the following criteria:</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">All of the following:</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">1 No evidence of disease progression; and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">2 The treatment remains appropriate and the patient is benefitting from treatment</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">\xa0</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">Notes: Lenvatinib with everolimus treatment should be stopped if disease progresses.</span></p><p>1.1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee made this recommendation based on the high and urgent unmet health need for patients with clear cell, metastatic renal cell carcinoma, with a lack of second-line treatment options for these patients, evidence of efficacy for lenvatinib with everolimus for improved progression-free survival, noting the difficulty of interpreting the data presented in the New Zealand context where checkpoint inhibitors are not funded for RCC.\xa0</p><p>1.1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee <b>recommended</b> that the use of tyrosine kinase inhibitors (including sunitinib, and pazopanib) for the second-line treatment of patients with metastatic renal cell carcinoma be deferred pending a review of the entire renal cell carcinoma treatment setting.\xa0</p>', 'fs': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee <b>recommended</b> that lenvatinib in combination with everolimus be funded for patients with advanced renal cell carcinoma who have progressed after one prior targeted therapy for the second-line treatment of patients with metastatic renal cell carcinoma with a <b>medium priority</b>, within the context of treatment of malignancy, subject to the following Special Authority criteria:\xa0\xa0</p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">LENVATINIB</span></p><p style=""text-align: justify;""><b style=""font-size: 9pt;"">Initial application</b><span style=""font-size: 9pt;""> from a relevant specialist or any other medical practitioner on the recommendation of a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria:</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">All of the following:</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">1 The patient has metastatic clear cell renal cell carcinoma; and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">2 The patient has received one prior line of targeted treatment; and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">3 The patient has good performance status (WHO/ECOG grade 0-1); and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">4 Lenvatinib with be prescribed in combination with everolimus </span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">\xa0</span></p><p style=""text-align: justify;""><b style=""font-size: 9pt;"">Renewal –</b><span style=""font-size: 9pt;""> (renal cell carcinoma) only from a relevant oncologist or gastroenterologist or hepatologist. Approvals valid for 3 months for applications meeting the following criteria:</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">All of the following:</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">1 No evidence of disease progression; and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">2 The treatment remains appropriate and the patient is benefitting from treatment</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">\xa0</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">Notes: Lenvatinib with everolimus treatment should be stopped if disease progresses.</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">\xa0</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">\xa0</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">EVEROLIMUS</span></p><p style=""text-align: justify;""><b style=""font-size: 9pt;"">Initial application</b><span style=""font-size: 9pt;""> — (RCC in combination with lenvatinib) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria:</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">1 The patient has histologically verified metastatic clear cell renal cell carcinoma; and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">2 The patient has received one prior line of targeted treatment; and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">3 Must be used in combination with lenvatinib </span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">\xa0</span></p><p style=""text-align: justify;""><b style=""font-size: 9pt;"">Renewal –</b><span style=""font-size: 9pt;""> (RCC in combination with lenvatinib) only from a relevant oncologist or gastroenterologist or hepatologist. Approvals valid for 3 months for applications meeting the following criteria:</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">All of the following:</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">1 No evidence of disease progression; and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">2 The treatment remains appropriate and the patient is benefitting from treatment</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">\xa0</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">Notes: Lenvatinib with everolimus treatment should be stopped if disease progresses.</span></p><p>1.1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee made this recommendation based on the high and urgent unmet health need for patients with clear cell, metastatic renal cell carcinoma, with a lack of second-line treatment options for these patients, evidence of efficacy for lenvatinib with everolimus for improved progression-free survival, noting the difficulty of interpreting the data presented in the New Zealand context where checkpoint inhibitors are not funded for RCC.\xa0</p><p>1.1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee <b>recommended</b> that the use of tyrosine kinase inhibitors (including sunitinib, and pazopanib) for the second-line treatment of patients with metastatic renal cell carcinoma be deferred pending a review of the entire renal cell carcinoma treatment setting.\xa0</p>', 'change': None}, 'Published_Discussion': {'s': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that there are currently no funded second-line targeted treatments for renal cell carcinoma (RCC) in New Zealand, and that treatment options are limited, and are not consistent with best practice recognised internationally. The Subcommittee noted that the health need for patients with RCC who have progressed after first-line targeted therapy (currently funded sunitinib or pazopanib) is high, and that most patients with intermediate or high risk disease will progress and would benefit from access to a second-line targeted therapy.</p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that since the introduction of targeted therapies in 2005, patients with advanced or metastatic RCC as a group have a median overall survival of 9.0 months, a 1-year survival of 38%, and a 3-year survival of 17% (<a href=""https://pubmed.ncbi.nlm.nih.gov/26645975/"" target=""_blank"" style=""font-size: 12pt;""><b>Li et al. Cancer Med. 2016;5:169-81</b></a>). The Subcommittee considered that the health needs of patients, families, and whānau of RCC patients is similar to that of many untreated progressive cancers, in that the average age of diagnosis is 65, there is a progressive loss of quality of life for patients and whānau, eventually culminating in the death of the patient.</p><p><span style=""color: black;"">1.3.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted the incidence of kidney cancer in New Zealand has been stable since 2008, and that risk factors include smoking, obesity, hypertension, acute diabetes, male sex, and possibly occupational exposure to solvents, petroleum products, asbestos and heavy metals. The Subcommittee noted that Māori have consistently higher rates of kidney cancer than non-Māori, and that an Otago University study in 2014 reported that Māori kidney cancer patients were 52% more likely to die of their cancer than non-Māori (<a href=""https://www.otago.ac.nz/wellington/otago067851.pdf"" target=""_blank"" style=""font-size: 12pt;""><b>Sarfati et al. 2014. Wellington: University of Otago</b></a>).</p><p><span style=""color: black;"">1.4.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that lenvatinib is a multiple tyrosine kinase inhibitor (TKI) that inhibits the kinase activities of vascular endothelial growth factor receptors and other proangiogenic and oncogenic pathway related receptor tyrosine kinases, which must be used in combination with everolimus, an orally administered mammalian target of rapamycin (mTOR) inhibitor. The Subcommittee also noted two other TKIs under consideration:</p><p>10.9.1<span style=""font-size: 7pt;"">\xa0\xa0</span>sunitinib, an orally administered therapy which works by blocking tyrosine kinases (receptors for platelet-derived growth factor and vascular endothelial growth factor), thus inhibiting cellular signalling, angiogenesis, and growth-stimulating proteins in the cancer cell itself; and</p><p>1.4.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>pazopanib, an orally administered, potent multi-target TKI of Vascular Endothelial Growth Factor Receptors (VEGFR)-1, -2, and -3, platelet-derived growth factor receptor (PDGFR)-α and –β, and stem cell factor receptor (c-KIT).</p><p><span style=""color: black;"">1.5.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that lenvatinib with everolimus, sunitinib, and pazopanib were all under consideration as second-line targeted treatments for clear cell metastatic RCC at this discussion.</p><p><span style=""color: black;"">1.6.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted a randomised, phase II, open label, multicentre trial (n=153) comparing the efficacy and safety of lenvatinib, everolimus, and lenvatinib plus everolimus treatment in patients with clear cell RCC and progressive or advanced disease who have had VEGF-targeted treatment (HOPE 205 trial, <a href=""https://pubmed.ncbi.nlm.nih.gov/26482279/"" target=""_blank"" style=""font-size: 12pt;""><b>Motzer et al. Lancet Oncol. 2015;1473-82</b></a>). The Subcommittee noted that lenvatinib plus everolimus significantly prolonged progression-free survival compared with everolimus alone (median 14.6 months [95% CI 5.9 to 20.1] vs 5.5 months [95% CI 3.5 to 7.1]; HR 0.40, 95% CI 0.24 to 0.68; p=0.0005).</p><p><span style=""color: black;"">1.7.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that in the post-hoc updated analysis (data cut-off 10 December 2014), the difference in overall survival between patients assigned lenvatinib with everolimus compared with those allocated single-agent everolimus was significantly increased (median overall survival 25·5 months vs 15·4 months; HR 0·51, 95% CI 0·30 to 0·88; p=0·024). The Subcommittee noted the study was not powered to assess overall survival and considered that prolonged follow-up with its small number of patients would mean significant uncertainty with the results.</p><p><span style=""color: black;"">1.8.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that although the trial indicated that lenvatinib with everolimus prolonged progression-free survival over either agent alone, the study was small, and the role of lenvatinib with everolimus following immune checkpoint inhibitors is uncertain. The Subcommittee also noted that the study was not blinded, and a longer follow-up was needed before a significant difference in outcomes was detected.</p><p><span style=""color: black;"">1.9.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted a phase III, multi-centre, randomised, double-blind, placebo-controlled trial (RECORD-1 trial), in which RCC patients were randomly assigned in a 2:1 ratio to receive everolimus (n=272) 10mg or placebo (n=138)\xa0with best supportive care (<a href=""https://pubmed.ncbi.nlm.nih.gov/18653228/"" target=""_blank"" style=""font-size: 12pt;""><b>Motzer et al. Lancet. 2008;372:449-56</b></a>). The Subcommittee noted that the results indicated a median progression free survival of 4 months with everolimus, compared to 1.9 in the placebo group (HR 0.30, 95% CI 0.22 to 0.40, p&lt;0.0001). The Subcommittee considered that this trial provided indirect supportive evidence for the use of lenvatinib with everolimus to treat RCC, and that there are no other studies comparing lenvatinib with everolimus to best supportive care. The Subcommittee also noted that everolimus is not funded or currently Medsafe approved for use in combination with lenvatinib for RCC.</p><p><span style=""color: black;"">1.10.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that the strength of evidence supporting the use of lenvatinib with everolimus in the second-line treatment of metastatic RCC was limited but of good quality. The Subcommittee did not identify any evidence for the use of sunitinib or pazopanib in the second-line setting following prior targeted therapy with the same agents. The Subcommittee also noted that some of the patients in the relevant trial had prior exposure to checkpoint inhibitors. As checkpoint inhibitors are not funded for the treatment of RCC in New Zealand, the Subcommittee considered that the results from the trial may not be relevant in a New Zealand patient context.\xa0</p><p><span style=""color: black;"">1.11.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the clinical risks of funding these treatments are related to expected side effects of each individual TKI agent. The Subcommittee noted that increased fatigue, hypertension, diarrhoea, and proteinuria are known class side-effects of VEGF-targeting agents, and that major side effects of mTOR inhibitors include stomatitis, rash, fatigue, and pneumonitis. The Subcommittee considered that, if these agents were to be funded for second-line use, additional benefits would accrue from increased progression-free survival for a group of cancer patients who have no funded treatments currently other than best supportive care. The Subcommittee noted that lenvatinib with everolimus, sunitinib, and pazopanib are not preferred second-line therapies in international practice for the treatment of RCC.</p><p><span style=""color: black;"">1.12.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that if one or more TKIs were to be funded for the second line treatment of RCC, that there would be limited consequences for the health system, apart from an increased need for monitoring of patients for expected toxicities, as dose adjustments are frequently required with these agents to manage adverse events. The Subcommittee considered that approximately 60 new patients per year would require second-line therapies for metastatic RCC.</p><p><span style=""color: black;"">1.13.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that, because New Zealand does not currently fund preferred treatments for RCC that are recommended in international treatment guidelines, there should be a broader review of the whole RCC treatment setting, where current treatments and internationally recommended treatments can be assessed together in the context of the New Zealand patient population. The Subcommittee would also welcome applications for combination use checkpoint inhibitors, such as nivolumab, for both first and second line RCC treatments. The Subcommittee also considered that PHARMAC staff should engage with clinical specialists directly such as the Genitourinary Special Interest Group of the NZ Society for Oncology (GU SIG NZSO) regarding the overall treatment landscape for RCC in New Zealand.\xa0</p>', 'fs': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that there are currently no funded second-line targeted treatments for renal cell carcinoma (RCC) in New Zealand, and that treatment options are limited, and are not consistent with best practice recognised internationally. The Subcommittee noted that the health need for patients with RCC who have progressed after first-line targeted therapy (currently funded sunitinib or pazopanib) is high, and that most patients with intermediate or high risk disease will progress and would benefit from access to a second-line targeted therapy.</p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that since the introduction of targeted therapies in 2005, patients with advanced or metastatic RCC as a group have a median overall survival of 9.0 months, a 1-year survival of 38%, and a 3-year survival of 17% (<a href=""https://pubmed.ncbi.nlm.nih.gov/26645975/"" target=""_blank"" style=""font-size: 12pt;""><b>Li et al. Cancer Med. 2016;5:169-81</b></a>). The Subcommittee considered that the health needs of patients, families, and whānau of RCC patients is similar to that of many untreated progressive cancers, in that the average age of diagnosis is 65, there is a progressive loss of quality of life for patients and whānau, eventually culminating in the death of the patient.</p><p><span style=""color: black;"">1.3.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted the incidence of kidney cancer in New Zealand has been stable since 2008, and that risk factors include smoking, obesity, hypertension, acute diabetes, male sex, and possibly occupational exposure to solvents, petroleum products, asbestos and heavy metals. The Subcommittee noted that Māori have consistently higher rates of kidney cancer than non-Māori, and that an Otago University study in 2014 reported that Māori kidney cancer patients were 52% more likely to die of their cancer than non-Māori (<a href=""https://www.otago.ac.nz/wellington/otago067851.pdf"" target=""_blank"" style=""font-size: 12pt;""><b>Sarfati et al. 2014. Wellington: University of Otago</b></a>).</p><p><span style=""color: black;"">1.4.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that lenvatinib is a multiple tyrosine kinase inhibitor (TKI) that inhibits the kinase activities of vascular endothelial growth factor receptors and other proangiogenic and oncogenic pathway related receptor tyrosine kinases, which must be used in combination with everolimus, an orally administered mammalian target of rapamycin (mTOR) inhibitor. The Subcommittee also noted two other TKIs under consideration:</p><p>10.9.1<span style=""font-size: 7pt;"">\xa0\xa0</span>sunitinib, an orally administered therapy which works by blocking tyrosine kinases (receptors for platelet-derived growth factor and vascular endothelial growth factor), thus inhibiting cellular signalling, angiogenesis, and growth-stimulating proteins in the cancer cell itself; and</p><p>1.4.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>pazopanib, an orally administered, potent multi-target TKI of Vascular Endothelial Growth Factor Receptors (VEGFR)-1, -2, and -3, platelet-derived growth factor receptor (PDGFR)-α and –β, and stem cell factor receptor (c-KIT).</p><p><span style=""color: black;"">1.5.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that lenvatinib with everolimus, sunitinib, and pazopanib were all under consideration as second-line targeted treatments for clear cell metastatic RCC at this discussion.</p><p><span style=""color: black;"">1.6.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted a randomised, phase II, open label, multicentre trial (n=153) comparing the efficacy and safety of lenvatinib, everolimus, and lenvatinib plus everolimus treatment in patients with clear cell RCC and progressive or advanced disease who have had VEGF-targeted treatment (HOPE 205 trial, <a href=""https://pubmed.ncbi.nlm.nih.gov/26482279/"" target=""_blank"" style=""font-size: 12pt;""><b>Motzer et al. Lancet Oncol. 2015;1473-82</b></a>). The Subcommittee noted that lenvatinib plus everolimus significantly prolonged progression-free survival compared with everolimus alone (median 14.6 months [95% CI 5.9 to 20.1] vs 5.5 months [95% CI 3.5 to 7.1]; HR 0.40, 95% CI 0.24 to 0.68; p=0.0005).</p><p><span style=""color: black;"">1.7.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that in the post-hoc updated analysis (data cut-off 10 December 2014), the difference in overall survival between patients assigned lenvatinib with everolimus compared with those allocated single-agent everolimus was significantly increased (median overall survival 25·5 months vs 15·4 months; HR 0·51, 95% CI 0·30 to 0·88; p=0·024). The Subcommittee noted the study was not powered to assess overall survival and considered that prolonged follow-up with its small number of patients would mean significant uncertainty with the results.</p><p><span style=""color: black;"">1.8.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that although the trial indicated that lenvatinib with everolimus prolonged progression-free survival over either agent alone, the study was small, and the role of lenvatinib with everolimus following immune checkpoint inhibitors is uncertain. The Subcommittee also noted that the study was not blinded, and a longer follow-up was needed before a significant difference in outcomes was detected.</p><p><span style=""color: black;"">1.9.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted a phase III, multi-centre, randomised, double-blind, placebo-controlled trial (RECORD-1 trial), in which RCC patients were randomly assigned in a 2:1 ratio to receive everolimus (n=272) 10mg or placebo (n=138)\xa0with best supportive care (<a href=""https://pubmed.ncbi.nlm.nih.gov/18653228/"" target=""_blank"" style=""font-size: 12pt;""><b>Motzer et al. Lancet. 2008;372:449-56</b></a>). The Subcommittee noted that the results indicated a median progression free survival of 4 months with everolimus, compared to 1.9 in the placebo group (HR 0.30, 95% CI 0.22 to 0.40, p&lt;0.0001). The Subcommittee considered that this trial provided indirect supportive evidence for the use of lenvatinib with everolimus to treat RCC, and that there are no other studies comparing lenvatinib with everolimus to best supportive care. The Subcommittee also noted that everolimus is not funded or currently Medsafe approved for use in combination with lenvatinib for RCC.</p><p><span style=""color: black;"">1.10.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that the strength of evidence supporting the use of lenvatinib with everolimus in the second-line treatment of metastatic RCC was limited but of good quality. The Subcommittee did not identify any evidence for the use of sunitinib or pazopanib in the second-line setting following prior targeted therapy with the same agents. The Subcommittee also noted that some of the patients in the relevant trial had prior exposure to checkpoint inhibitors. As checkpoint inhibitors are not funded for the treatment of RCC in New Zealand, the Subcommittee considered that the results from the trial may not be relevant in a New Zealand patient context.\xa0</p><p><span style=""color: black;"">1.11.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the clinical risks of funding these treatments are related to expected side effects of each individual TKI agent. The Subcommittee noted that increased fatigue, hypertension, diarrhoea, and proteinuria are known class side-effects of VEGF-targeting agents, and that major side effects of mTOR inhibitors include stomatitis, rash, fatigue, and pneumonitis. The Subcommittee considered that, if these agents were to be funded for second-line use, additional benefits would accrue from increased progression-free survival for a group of cancer patients who have no funded treatments currently other than best supportive care. The Subcommittee noted that lenvatinib with everolimus, sunitinib, and pazopanib are not preferred second-line therapies in international practice for the treatment of RCC.</p><p><span style=""color: black;"">1.12.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that if one or more TKIs were to be funded for the second line treatment of RCC, that there would be limited consequences for the health system, apart from an increased need for monitoring of patients for expected toxicities, as dose adjustments are frequently required with these agents to manage adverse events. The Subcommittee considered that approximately 60 new patients per year would require second-line therapies for metastatic RCC.</p><p><span style=""color: black;"">1.13.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that, because New Zealand does not currently fund preferred treatments for RCC that are recommended in international treatment guidelines, there should be a broader review of the whole RCC treatment setting, where current treatments and internationally recommended treatments can be assessed together in the context of the New Zealand patient population. The Subcommittee would also welcome applications for combination use checkpoint inhibitors, such as nivolumab, for both first and second line RCC treatments. The Subcommittee also considered that PHARMAC staff should engage with clinical specialists directly such as the Genitourinary Special Interest Group of the NZ Society for Oncology (GU SIG NZSO) regarding the overall treatment landscape for RCC in New Zealand.\xa0</p>', 'change': None}, 'Published_Application': {'s': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee reviewed the application for from a supplier (Eisai) for the use of lenvatinib in combination with everolimus for the second-line treatment of patients with advanced renal cell carcinoma (RCC) who have progressed after one prior vascular endothelial growth factor (VEGF) targeted therapy.</p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee also reviewed, as part of a separate clinician application, the use of tyrosine kinase inhibitors sunitinib and pazopanib in the second-line setting for metastatic RCC.</p><p><span style=""color: black;"">1.3.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee took into account, where applicable, PHARMAC’s relevant decision-making framework when considering this agenda item.</p>', 'fs': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee reviewed the application for from a supplier (Eisai) for the use of lenvatinib in combination with everolimus for the second-line treatment of patients with advanced renal cell carcinoma (RCC) who have progressed after one prior vascular endothelial growth factor (VEGF) targeted therapy.</p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee also reviewed, as part of a separate clinician application, the use of tyrosine kinase inhibitors sunitinib and pazopanib in the second-line setting for metastatic RCC.</p><p><span style=""color: black;"">1.3.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee took into account, where applicable, PHARMAC’s relevant decision-making framework when considering this agenda item.</p>', 'change': None}, 'PTAC_Comments': {'s': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>In regards to items 6 and 7 and CaTSoP’s consideration of tyrosine kinase inhibitors e.g. sunitinib, pazopanib, lenvatinib:</p><p>1.1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted the Subcommittee’s recommendations, and also that it had suggested a broader review of the RCC treatment landscape in New Zealand and internationally, including with feedback from specialist groups such as the Genitourinary cancers special interest group.\xa0</p>', 'fs': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>In regards to items 6 and 7 and CaTSoP’s consideration of tyrosine kinase inhibitors e.g. sunitinib, pazopanib, lenvatinib:</p><p>1.1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted the Subcommittee’s recommendations, and also that it had suggested a broader review of the RCC treatment landscape in New Zealand and internationally, including with feedback from specialist groups such as the Genitourinary cancers special interest group.\xa0</p>', 'change': None}, 'Outcome': {'s': 'Medium', 'fs': 'Medium', 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Feb 2021', 'fs': 'Feb 2021', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Cancer Treatments Subcommittee (CaTSoP) at meeting Friday 16 October 2020.', 'fs': 'Clinical advice received from Cancer Treatments Subcommittee (CaTSoP) at meeting Friday 16 October 2020.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000EZ28k2AD'}, 'Id': 'a0POZ00000EZ28k2AD', 'Event_Date__c': '2021-02-25', 'Event_Description__c': 'Clinical advice received from Cancer Treatments Subcommittee (CaTSoP) at meeting Friday 16 October 2020.', 'Stage__c': 'Seeking Clinical Advice', 'Outcome__c': 'Medium', 'Formatted_Date__c': 'Feb 2021', 'Published_Recommendation__c': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee <b>recommended</b> that lenvatinib in combination with everolimus be funded for patients with advanced renal cell carcinoma who have progressed after one prior targeted therapy for the second-line treatment of patients with metastatic renal cell carcinoma with a <b>medium priority</b>, within the context of treatment of malignancy, subject to the following Special Authority criteria:\xa0\xa0</p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">LENVATINIB</span></p><p style=""text-align: justify;""><b style=""font-size: 9pt;"">Initial application</b><span style=""font-size: 9pt;""> from a relevant specialist or any other medical practitioner on the recommendation of a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria:</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">All of the following:</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">1 The patient has metastatic clear cell renal cell carcinoma; and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">2 The patient has received one prior line of targeted treatment; and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">3 The patient has good performance status (WHO/ECOG grade 0-1); and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">4 Lenvatinib with be prescribed in combination with everolimus </span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">\xa0</span></p><p style=""text-align: justify;""><b style=""font-size: 9pt;"">Renewal –</b><span style=""font-size: 9pt;""> (renal cell carcinoma) only from a relevant oncologist or gastroenterologist or hepatologist. Approvals valid for 3 months for applications meeting the following criteria:</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">All of the following:</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">1 No evidence of disease progression; and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">2 The treatment remains appropriate and the patient is benefitting from treatment</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">\xa0</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">Notes: Lenvatinib with everolimus treatment should be stopped if disease progresses.</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">\xa0</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">\xa0</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">EVEROLIMUS</span></p><p style=""text-align: justify;""><b style=""font-size: 9pt;"">Initial application</b><span style=""font-size: 9pt;""> — (RCC in combination with lenvatinib) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria:</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">1 The patient has histologically verified metastatic clear cell renal cell carcinoma; and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">2 The patient has received one prior line of targeted treatment; and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">3 Must be used in combination with lenvatinib </span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">\xa0</span></p><p style=""text-align: justify;""><b style=""font-size: 9pt;"">Renewal –</b><span style=""font-size: 9pt;""> (RCC in combination with lenvatinib) only from a relevant oncologist or gastroenterologist or hepatologist. Approvals valid for 3 months for applications meeting the following criteria:</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">All of the following:</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">1 No evidence of disease progression; and</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">2 The treatment remains appropriate and the patient is benefitting from treatment</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">\xa0</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">Notes: Lenvatinib with everolimus treatment should be stopped if disease progresses.</span></p><p>1.1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee made this recommendation based on the high and urgent unmet health need for patients with clear cell, metastatic renal cell carcinoma, with a lack of second-line treatment options for these patients, evidence of efficacy for lenvatinib with everolimus for improved progression-free survival, noting the difficulty of interpreting the data presented in the New Zealand context where checkpoint inhibitors are not funded for RCC.\xa0</p><p>1.1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee <b>recommended</b> that the use of tyrosine kinase inhibitors (including sunitinib, and pazopanib) for the second-line treatment of patients with metastatic renal cell carcinoma be deferred pending a review of the entire renal cell carcinoma treatment setting.\xa0</p>', 'Published_Application__c': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee reviewed the application for from a supplier (Eisai) for the use of lenvatinib in combination with everolimus for the second-line treatment of patients with advanced renal cell carcinoma (RCC) who have progressed after one prior vascular endothelial growth factor (VEGF) targeted therapy.</p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee also reviewed, as part of a separate clinician application, the use of tyrosine kinase inhibitors sunitinib and pazopanib in the second-line setting for metastatic RCC.</p><p><span style=""color: black;"">1.3.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee took into account, where applicable, PHARMAC’s relevant decision-making framework when considering this agenda item.</p>', 'Published_Discussion__c': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that there are currently no funded second-line targeted treatments for renal cell carcinoma (RCC) in New Zealand, and that treatment options are limited, and are not consistent with best practice recognised internationally. The Subcommittee noted that the health need for patients with RCC who have progressed after first-line targeted therapy (currently funded sunitinib or pazopanib) is high, and that most patients with intermediate or high risk disease will progress and would benefit from access to a second-line targeted therapy.</p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that since the introduction of targeted therapies in 2005, patients with advanced or metastatic RCC as a group have a median overall survival of 9.0 months, a 1-year survival of 38%, and a 3-year survival of 17% (<a href=""https://pubmed.ncbi.nlm.nih.gov/26645975/"" target=""_blank"" style=""font-size: 12pt;""><b>Li et al. Cancer Med. 2016;5:169-81</b></a>). The Subcommittee considered that the health needs of patients, families, and whānau of RCC patients is similar to that of many untreated progressive cancers, in that the average age of diagnosis is 65, there is a progressive loss of quality of life for patients and whānau, eventually culminating in the death of the patient.</p><p><span style=""color: black;"">1.3.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted the incidence of kidney cancer in New Zealand has been stable since 2008, and that risk factors include smoking, obesity, hypertension, acute diabetes, male sex, and possibly occupational exposure to solvents, petroleum products, asbestos and heavy metals. The Subcommittee noted that Māori have consistently higher rates of kidney cancer than non-Māori, and that an Otago University study in 2014 reported that Māori kidney cancer patients were 52% more likely to die of their cancer than non-Māori (<a href=""https://www.otago.ac.nz/wellington/otago067851.pdf"" target=""_blank"" style=""font-size: 12pt;""><b>Sarfati et al. 2014. Wellington: University of Otago</b></a>).</p><p><span style=""color: black;"">1.4.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that lenvatinib is a multiple tyrosine kinase inhibitor (TKI) that inhibits the kinase activities of vascular endothelial growth factor receptors and other proangiogenic and oncogenic pathway related receptor tyrosine kinases, which must be used in combination with everolimus, an orally administered mammalian target of rapamycin (mTOR) inhibitor. The Subcommittee also noted two other TKIs under consideration:</p><p>10.9.1<span style=""font-size: 7pt;"">\xa0\xa0</span>sunitinib, an orally administered therapy which works by blocking tyrosine kinases (receptors for platelet-derived growth factor and vascular endothelial growth factor), thus inhibiting cellular signalling, angiogenesis, and growth-stimulating proteins in the cancer cell itself; and</p><p>1.4.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>pazopanib, an orally administered, potent multi-target TKI of Vascular Endothelial Growth Factor Receptors (VEGFR)-1, -2, and -3, platelet-derived growth factor receptor (PDGFR)-α and –β, and stem cell factor receptor (c-KIT).</p><p><span style=""color: black;"">1.5.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted that lenvatinib with everolimus, sunitinib, and pazopanib were all under consideration as second-line targeted treatments for clear cell metastatic RCC at this discussion.</p><p><span style=""color: black;"">1.6.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted a randomised, phase II, open label, multicentre trial (n=153) comparing the efficacy and safety of lenvatinib, everolimus, and lenvatinib plus everolimus treatment in patients with clear cell RCC and progressive or advanced disease who have had VEGF-targeted treatment (HOPE 205 trial, <a href=""https://pubmed.ncbi.nlm.nih.gov/26482279/"" target=""_blank"" style=""font-size: 12pt;""><b>Motzer et al. Lancet Oncol. 2015;1473-82</b></a>). The Subcommittee noted that lenvatinib plus everolimus significantly prolonged progression-free survival compared with everolimus alone (median 14.6 months [95% CI 5.9 to 20.1] vs 5.5 months [95% CI 3.5 to 7.1]; HR 0.40, 95% CI 0.24 to 0.68; p=0.0005).</p><p><span style=""color: black;"">1.7.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that in the post-hoc updated analysis (data cut-off 10 December 2014), the difference in overall survival between patients assigned lenvatinib with everolimus compared with those allocated single-agent everolimus was significantly increased (median overall survival 25·5 months vs 15·4 months; HR 0·51, 95% CI 0·30 to 0·88; p=0·024). The Subcommittee noted the study was not powered to assess overall survival and considered that prolonged follow-up with its small number of patients would mean significant uncertainty with the results.</p><p><span style=""color: black;"">1.8.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that although the trial indicated that lenvatinib with everolimus prolonged progression-free survival over either agent alone, the study was small, and the role of lenvatinib with everolimus following immune checkpoint inhibitors is uncertain. The Subcommittee also noted that the study was not blinded, and a longer follow-up was needed before a significant difference in outcomes was detected.</p><p><span style=""color: black;"">1.9.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted a phase III, multi-centre, randomised, double-blind, placebo-controlled trial (RECORD-1 trial), in which RCC patients were randomly assigned in a 2:1 ratio to receive everolimus (n=272) 10mg or placebo (n=138)\xa0with best supportive care (<a href=""https://pubmed.ncbi.nlm.nih.gov/18653228/"" target=""_blank"" style=""font-size: 12pt;""><b>Motzer et al. Lancet. 2008;372:449-56</b></a>). The Subcommittee noted that the results indicated a median progression free survival of 4 months with everolimus, compared to 1.9 in the placebo group (HR 0.30, 95% CI 0.22 to 0.40, p&lt;0.0001). The Subcommittee considered that this trial provided indirect supportive evidence for the use of lenvatinib with everolimus to treat RCC, and that there are no other studies comparing lenvatinib with everolimus to best supportive care. The Subcommittee also noted that everolimus is not funded or currently Medsafe approved for use in combination with lenvatinib for RCC.</p><p><span style=""color: black;"">1.10.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that the strength of evidence supporting the use of lenvatinib with everolimus in the second-line treatment of metastatic RCC was limited but of good quality. The Subcommittee did not identify any evidence for the use of sunitinib or pazopanib in the second-line setting following prior targeted therapy with the same agents. The Subcommittee also noted that some of the patients in the relevant trial had prior exposure to checkpoint inhibitors. As checkpoint inhibitors are not funded for the treatment of RCC in New Zealand, the Subcommittee considered that the results from the trial may not be relevant in a New Zealand patient context.\xa0</p><p><span style=""color: black;"">1.11.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the clinical risks of funding these treatments are related to expected side effects of each individual TKI agent. The Subcommittee noted that increased fatigue, hypertension, diarrhoea, and proteinuria are known class side-effects of VEGF-targeting agents, and that major side effects of mTOR inhibitors include stomatitis, rash, fatigue, and pneumonitis. The Subcommittee considered that, if these agents were to be funded for second-line use, additional benefits would accrue from increased progression-free survival for a group of cancer patients who have no funded treatments currently other than best supportive care. The Subcommittee noted that lenvatinib with everolimus, sunitinib, and pazopanib are not preferred second-line therapies in international practice for the treatment of RCC.</p><p><span style=""color: black;"">1.12.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that if one or more TKIs were to be funded for the second line treatment of RCC, that there would be limited consequences for the health system, apart from an increased need for monitoring of patients for expected toxicities, as dose adjustments are frequently required with these agents to manage adverse events. The Subcommittee considered that approximately 60 new patients per year would require second-line therapies for metastatic RCC.</p><p><span style=""color: black;"">1.13.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that, because New Zealand does not currently fund preferred treatments for RCC that are recommended in international treatment guidelines, there should be a broader review of the whole RCC treatment setting, where current treatments and internationally recommended treatments can be assessed together in the context of the New Zealand patient population. The Subcommittee would also welcome applications for combination use checkpoint inhibitors, such as nivolumab, for both first and second line RCC treatments. The Subcommittee also considered that PHARMAC staff should engage with clinical specialists directly such as the Genitourinary Special Interest Group of the NZ Society for Oncology (GU SIG NZSO) regarding the overall treatment landscape for RCC in New Zealand.\xa0</p>', 'PTAC_Comments__c': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>In regards to items 6 and 7 and CaTSoP’s consideration of tyrosine kinase inhibitors e.g. sunitinib, pazopanib, lenvatinib:</p><p>1.1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted the Subcommittee’s recommendations, and also that it had suggested a broader review of the RCC treatment landscape in New Zealand and internationally, including with feedback from specialist groups such as the Genitourinary cancers special interest group.\xa0</p>', 'Status_History__c': 'a132P000000CdHGQA0'}, 'change': None}]",Jul 2020,False,True
2,"<p>Following Clinical Advice, Pharmac staff considers the advice and the funding application under goes an assessment using our&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/factors-for-consideration/"" rel=""nofollow"">Factors for Consideration</a>&nbsp;framework and seeks additional information as required.</p>
<p>&nbsp;</p>
<p>Research and Economic analysis are undertaken.&nbsp; This focuses on the costs and benefits of a proposed course of action. Economics is based on three fundamental concepts that summarise the issues Pharmac faces daily:&nbsp;</p>
<ul>
<li>Scarcity &ndash; resources will always be insufficient to support all possible activities.</li>
<li>Choices &ndash; due to scarce resources, decisions must be made about how best to use them.</li>
<li>Opportunity cost &ndash; by choosing to use resources one way, we forgo other opportunities to use the same resources.</li>
</ul>
<p>&nbsp;</p>
<p>For further information on the purpose of, and techniques for, undertaking economic analysis in health care, please refer&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/</a></p>",2,Under Assessment,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Mar 2021', 'fs': 'Mar 2021', 'change': None}, 'Event_Description': {'s': 'Working to compare options', 'fs': 'Working to compare options', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000EZ28l2AD'}, 'Id': 'a0POZ00000EZ28l2AD', 'Event_Date__c': '2021-03-28', 'Event_Description__c': 'Working to compare options', 'Stage__c': 'Under Assessment', 'Formatted_Date__c': 'Mar 2021', 'Status_History__c': 'a132P000000CifRQAS'}, 'change': None}]",Mar 2021,False,True
3,"<p>Pharmac staff uses a prioritisation process to compare and rank funding options. Possible opportunities for new investment will always exceed the budget Pharmac has available; therefore, prioritisation is an intrinsic part of Pharmac’s decision-making process.</p>
<p>The relative ranking of options aims to support Pharmac&rsquo;s statutory objective &ldquo;to secure for eligible people in need of pharmaceuticals, the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided&rdquo;.</p>
<p>A funding application or proposal is considered ready for prioritisation when sufficient information is available to permit it to be reviewed against Pharmac's Factors for Consideration and to inform a comparison with other possible investment decisions.</p>
<p>There is no guarantee when or if a ranked medicine will be funded.&nbsp;&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/</a></p>",3,Options Compared,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jun 2021', 'fs': 'Jun 2021', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000EZ28m2AD'}, 'Id': 'a0POZ00000EZ28m2AD', 'Event_Date__c': '2021-06-09', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'Jun 2021', 'Status_History__c': 'a132P000000CuoeQAC'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Mar 2022', 'fs': 'Mar 2022', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000EZ28n2AD'}, 'Id': 'a0POZ00000EZ28n2AD', 'Event_Date__c': '2022-03-04', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'Mar 2022', 'Status_History__c': 'a132P000000DaPyQAK'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Mar 2023', 'fs': 'Mar 2023', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000EZ28o2AD'}, 'Id': 'a0POZ00000EZ28o2AD', 'Event_Date__c': '2023-03-09', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'Mar 2023', 'Status_History__c': 'a132P000000EDT4QAO'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jun 2023', 'fs': 'Jun 2023', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000EZ28p2AD'}, 'Id': 'a0POZ00000EZ28p2AD', 'Event_Date__c': '2023-06-12', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'Jun 2023', 'Status_History__c': 'a132P000000EOP6QAO'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Sep 2023', 'fs': 'Sep 2023', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000EZ28q2AD'}, 'Id': 'a0POZ00000EZ28q2AD', 'Event_Date__c': '2023-09-08', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'Sep 2023', 'Status_History__c': 'a13OZ000001vnurYAA'}, 'change': None}]",Jun 2021,False,True
4,"<p>Pharmac is consulting on a proposal to either approve or decline the application.&nbsp;We seek the views of all people who have an interest in our proposals, or who may be affected by them, to obtain feedback on our proposed approaches.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/</a></p>",4,Under Consultation,False,"[{'Summary': {'s': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2024-09-lenvatinib-consultation"" target=""_blank"">Consultation notification</a></p>', 'fs': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2024-09-lenvatinib-consultation"" target=""_blank"">Consultation notification</a></p>', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Sep 2024', 'fs': 'Sep 2024', 'change': None}, 'Event_Description': {'s': 'Public consultation for this application is active.', 'fs': 'Public consultation for this application is active.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000EZ28r2AD'}, 'Id': 'a0POZ00000EZ28r2AD', 'Event_Date__c': '2024-09-18', 'Event_Description__c': 'Public consultation for this application is active.', 'Stage__c': 'Under Consultation', 'Summary__c': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2024-09-lenvatinib-consultation"" target=""_blank"">Consultation notification</a></p>', 'Formatted_Date__c': 'Sep 2024', 'Status_History__c': 'a13OZ00000EMG32YAH'}, 'change': None}]",Sep 2024,False,True
5,"<p>Following the consultation process, Pharmac staff considers the feedback and identifies any additional information required as part of a gap analysis.&nbsp; The proposal may require further clinical advice, research, and assessment.</p>",5,Reviewing Consultation Feedback,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Oct 2024', 'fs': 'Oct 2024', 'change': None}, 'Event_Description': {'s': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'fs': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000EZ28s2AD'}, 'Id': 'a0POZ00000EZ28s2AD', 'Event_Date__c': '2024-10-04', 'Event_Description__c': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'Stage__c': 'Reviewing Consultation Feedback', 'Formatted_Date__c': 'Oct 2024', 'Status_History__c': 'a13OZ00000Ez4eXYAR'}, 'change': None}]",Oct 2024,False,True
6,"<p>We refer to our decisions about whether and how particular pharmaceuticals are publicly-funded, as &ldquo;funding decisions&rdquo;.</p>
<p>We consider and assess all funding decisions using the&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/about/operating-policies-and-procedures/#factorsfc"" rel=""nofollow"">Factors for Consideration</a>. When we do so, we carefully evaluate clinical and other evidence for the benefits and suitability of a proposal, and to identify and understand the people who will be affected by it.</p>
<p>While our main task is to allocate pharmaceutical funding, we consider the benefits and costs across the whole health system now and with a long-term focus, including the effects for hospitals and primary care, and consider direct costs to patients as well as to all health sector budgets.</p>
<p>Final funding decisions are made by the Pharmac Board or delegated to senior Pharmac staff as required by the Board.</p>
<p>&nbsp;</p>",6,Decision,True,"[{'Summary': {'s': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/f-decision-to-fund-lenvatinib-for-thyroid-liver-and-kidney-cancers"" target=""_blank"">Notification</a></p>', 'fs': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/f-decision-to-fund-lenvatinib-for-thyroid-liver-and-kidney-cancers"" target=""_blank"">Notification</a></p>', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Nov 2024', 'fs': 'Nov 2024', 'change': None}, 'Event_Description': {'s': 'The funding application has been approved.', 'fs': 'The funding application has been approved.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000EZ28t2AD'}, 'Id': 'a0POZ00000EZ28t2AD', 'Event_Date__c': '2024-11-06', 'Event_Description__c': 'The funding application has been approved.', 'Stage__c': 'Decision', 'Summary__c': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/f-decision-to-fund-lenvatinib-for-thyroid-liver-and-kidney-cancers"" target=""_blank"">Notification</a></p>', 'Formatted_Date__c': 'Nov 2024', 'Status_History__c': 'a13OZ00000GGijqYAD'}, 'change': None}]",Nov 2024,False,True
